How did the court ruling affect Amgen's stock?

The ruling removed a regulatory overhang, supporting the stock's positive momentum. AMGN has returned 8.48% over 30 days and 11.78% year-to-date.

Are there similar cases in other states?

Yes, states like Maryland have attempted drug price caps, but courts have previously struck them down.

Court Ruling Removes Enbrel Pricing Overhang for Amgen

A U.S. court has blocked Colorado's planned 70% price cap on Amgen's (AMGN) Enbrel, removing a significant regulatory overhang. The stock has been building positive momentum with strong short- and long-term returns.

July 22, 2026

2 min read

Source: Simply Wall St.

Key Numbers

30 day return

8.48%

ytd return

11.78%

1 year return

23.41%

3 year return

70.66%

A federal court has blocked Colorado's planned 70% price cap on Enbrel, Amgen's (AMGN) rheumatoid arthritis drug, removing a key regulatory overhang that had weighed on the stock. The decision refocuses attention on the company's earnings fundamentals.

Details of the Action

Colorado had planned to impose a 70% price cap on Enbrel, one of Amgen's key drugs. However, a federal court ruled against the cap, citing conflicts with federal law.

Company's Position

Amgen welcomed the ruling, stating that drug pricing should be addressed at the national level, not by individual states. The company believes the decision protects its ability to invest in R&D.

Precedents and Context

This is not the first time states have attempted to cap drug prices. A similar law in Maryland was struck down in 2019. The current ruling reinforces the industry's stance against state-level price controls.

Potential Financial Impact

The removal of this regulatory uncertainty could support Enbrel revenues, which are a significant part of Amgen's portfolio. The stock has shown positive momentum with a 30-day return of 8.48%, YTD return of 11.78%, and 1-year and 3-year total shareholder returns of 23.41% and 70.66%, respectively.

Frequently Asked Questions

Enbrel is a biologic drug for rheumatoid arthritis and other autoimmune diseases, and is a key product for Amgen.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.